We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Sysmex and Roche Extend Hematology Alliance

By LabMedica International staff writers
Posted on 17 Apr 2012
Print article
Sysmex Corporation (Kobe, Japan) and Roche (Basel, Switzerland) signed a restated 10 years distribution, sales, and services agreement (DSS Agreement). The previous distributorship, sales, and services agreement will extend for another 10 years.

Roche will continue to distribute Sysmex hematology products, including instruments, reagents, and data management solutions in selected countries and regions. These include Spain, Turkey, Greece, South Africa, Russia, Finland, Baltic Territory, Brazil, Mexico, Chile, Argentina, Uruguay, Colombia, Peru, Ecuador, Venezuela, Central America, Australia, and New Zealand.

The recently released new XN series from Sysmex with its modular and scalable system design enables customer access to a full menu across customer segments from small to large workloads. Concurrent with Roche’s future platform strategy, the new Sysmex XN series contributes to Roche’s concept of addressing the various needs of today’s laboratories with customized modular solutions. The renewed agreement allows both companies to apply their strengths more effectively.

Since entering into the DSS Agreement in 1999, Sysmex and Roche have combined their mutual strengths to expand market share while building a positive relationship.

Hisashi Ietsugu, president and CEO of Sysmex Corp. commented, "Based on Sysmex’ industry leadership allied with Roche’s unique position as the global market leader in in-vitro diagnostics, the collaboration underlines our objective of bringing a maximum of industry expertise in hematology to health professionals. This unique synergy supports both companies’ objectives to continue to grow above market."

Sysmex Corporation is a leader in clinical laboratory testing of blood, urine and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems as part of a comprehensive service and support system.

Roche Professional Diagnostics is Roche’s market-leading business area of integrated, modular, and highly efficient testing solutions for clinical and immune in vitro diagnostics for centralized and decentralized settings. Roche is also a leader in in-vitro diagnostics, tissue-based cancer diagnostics, and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life, and survival of patients.

Related Links:

Sysmex Corporation
Roche


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.